SOCS1 and stroke disorder: This offers a promising therapeutic strategy for IS, through modulation of uncontrolled inflammation in stroke-injured astrocytes by targeting the suppressor of cytokine signaling (SOCS-1) and M1-microglia (Table 1) [151].